Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 210441, held by Appco. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 210441 (Hydroxychloroquine Sulfate), held by Appco, was first approved by FDA on May 1, 2018, with 5 approved supplements and 0 published complete response letters.
Hydroxychloroquine Sulfate Tablets are an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. Treatment of rheumatoid arthritis in adults. Treatment of systemic lupus erythematosus in adults. Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: Hydroxychloroquine Sulfate Tablets are not recommended for the: Treatment of complicated malaria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 2018 | Original application | Approved |
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Hydroxychloroquine Sulfate100MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Hydroxychloroquine Sulfate300MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Hydroxychloroquine Sulfate400MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Oct 8, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 29, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 19, 2022 | Supplement 10Manufacturing | Approved | None posted |
| Jul 7, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 27, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 1, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters